Monash University biotech spinout Rage lands $29 million Series A
The round was led by IP Group Australia and super fund Hostplus, with support from existing investors including Monash Ventures. The funds will go towards first-in-human clinical trials for Rage’s nasal therapy to treat inflammatory lung diseases The startup’s name is an acronym of Receptor for Advanced Glycation End-products (RAGE), a receptor involved in inflammation in […]